449 related articles for article (PubMed ID: 25724523)
121. Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma.
Ekshyyan O; Rong Y; Rong X; Pattani KM; Abreo F; Caldito G; Chang JK; Ampil F; Glass J; Nathan CO
Mol Cancer Ther; 2009 Aug; 8(8):2255-65. PubMed ID: 19625495
[TBL] [Abstract][Full Text] [Related]
122. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.
Zhao Y; Thomas HD; Batey MA; Cowell IG; Richardson CJ; Griffin RJ; Calvert AH; Newell DR; Smith GC; Curtin NJ
Cancer Res; 2006 May; 66(10):5354-62. PubMed ID: 16707462
[TBL] [Abstract][Full Text] [Related]
123. G2-checkpoint targeting and radiosensitization of HPV/p16-positive HNSCC cells through the inhibition of Chk1 and Wee1.
Busch CJ; Kröger MS; Jensen J; Kriegs M; Gatzemeier F; Petersen C; Münscher A; Rothkamm K; Rieckmann T
Radiother Oncol; 2017 Feb; 122(2):260-266. PubMed ID: 27939202
[TBL] [Abstract][Full Text] [Related]
124. Effect of PF-02341066 and radiation on non-small cell lung cancer cells.
Tumati V; Kumar S; Yu L; Chen B; Choy H; Saha D
Oncol Rep; 2013 Mar; 29(3):1094-100. PubMed ID: 23254764
[TBL] [Abstract][Full Text] [Related]
125. Enhancement of Radiosensitivity by Eurycomalactone in Human NSCLC Cells Through G₂/M Cell Cycle Arrest and Delayed DNA Double-Strand Break Repair.
Dukaew N; Konishi T; Chairatvit K; Autsavapromporn N; Soonthornchareonnon N; Wongnoppavich A
Oncol Res; 2020 Mar; 28(2):161-175. PubMed ID: 31727206
[TBL] [Abstract][Full Text] [Related]
126. Resveratrol selectively induces DNA Damage, independent of Smad4 expression, in its efficacy against human head and neck squamous cell carcinoma.
Tyagi A; Gu M; Takahata T; Frederick B; Agarwal C; Siriwardana S; Agarwal R; Sclafani RA
Clin Cancer Res; 2011 Aug; 17(16):5402-11. PubMed ID: 21705453
[TBL] [Abstract][Full Text] [Related]
127. Exploiting the head and neck cancer oncogenome: widespread PI3K-mTOR pathway alterations and novel molecular targets.
Iglesias-Bartolome R; Martin D; Gutkind JS
Cancer Discov; 2013 Jul; 3(7):722-5. PubMed ID: 23847349
[TBL] [Abstract][Full Text] [Related]
128. CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma.
Zeng L; Nikolaev A; Xing C; Della Manna DL; Yang ES
Mol Cancer Ther; 2020 Jun; 19(6):1279-1288. PubMed ID: 32371584
[TBL] [Abstract][Full Text] [Related]
129. Targeting Aurora B kinase with Tanshinone IIA suppresses tumor growth and overcomes radioresistance.
Li M; Liu H; Zhao Q; Han S; Zhou L; Liu W; Li W; Gao F
Cell Death Dis; 2021 Feb; 12(2):152. PubMed ID: 33542222
[TBL] [Abstract][Full Text] [Related]
130. VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.
Hart S; Novotny-Diermayr V; Goh KC; Williams M; Tan YC; Ong LC; Cheong A; Ng BK; Amalini C; Madan B; Nagaraj H; Jayaraman R; Pasha KM; Ethirajulu K; Chng WJ; Mustafa N; Goh BC; Benes C; McDermott U; Garnett M; Dymock B; Wood JM
Mol Cancer Ther; 2013 Feb; 12(2):151-61. PubMed ID: 23270925
[TBL] [Abstract][Full Text] [Related]
131. Hedgehog signaling drives radioresistance and stroma-driven tumor repopulation in head and neck squamous cancers.
Gan GN; Eagles J; Keysar SB; Wang G; Glogowska MJ; Altunbas C; Anderson RT; Le PN; Morton JJ; Frederick B; Raben D; Wang XJ; Jimeno A
Cancer Res; 2014 Dec; 74(23):7024-36. PubMed ID: 25297633
[TBL] [Abstract][Full Text] [Related]
132. Isoalantolactone Enhances the Radiosensitivity of UMSCC-10A Cells via Specific Inhibition of Erk1/2 Phosphorylation.
Fan Y; Weng Z; Gao H; Hu J; Wang H; Li L; Liu H
PLoS One; 2015; 10(12):e0145790. PubMed ID: 26716456
[TBL] [Abstract][Full Text] [Related]
133. Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer.
Beale G; Haagensen EJ; Thomas HD; Wang LZ; Revill CH; Payne SL; Golding BT; Hardcastle IR; Newell DR; Griffin RJ; Cano C
Br J Cancer; 2016 Sep; 115(6):682-90. PubMed ID: 27529512
[TBL] [Abstract][Full Text] [Related]
134. Combined Erlotinib and PF-03084014 treatment contributes to synthetic lethality in head and neck squamous cell carcinoma.
Zheng Y; Wang Z; Ding X; Dong Y; Zhang W; Zhang W; Zhong Y; Gu W; Wu Y; Song X
Cell Prolif; 2018 Jun; 51(3):e12424. PubMed ID: 29232766
[TBL] [Abstract][Full Text] [Related]
135. Targeting irradiation-induced mitogen-activated protein kinase activation in vitro and in an ex vivo model for human head and neck cancer.
Affolter A; Muller MF; Sommer K; Stenzinger A; Zaoui K; Lorenz K; Wolf T; Sharma S; Wolf J; Perner S; Weber KJ; Freier K; Plinkert PK; Hess J; Weichert W
Head Neck; 2016 Apr; 38 Suppl 1():E2049-61. PubMed ID: 26918677
[TBL] [Abstract][Full Text] [Related]
136. Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice.
Nishikawa T; Takaoka M; Ohara T; Tomono Y; Hao H; Bao X; Fukazawa T; Wang Z; Sakurama K; Fujiwara Y; Motoki T; Shirakawa Y; Yamatsuji T; Tanaka N; Fujiwara T; Naomoto Y
Cancer Biol Ther; 2013 Mar; 14(3):230-6. PubMed ID: 23291985
[TBL] [Abstract][Full Text] [Related]
137. Pre-clinical characterization of Dacomitinib (PF-00299804), an irreversible pan-ErbB inhibitor, combined with ionizing radiation for head and neck squamous cell carcinoma.
Williams JP; Kim I; Ito E; Shi W; Yue S; Siu LL; Waldron J; O'Sullivan B; Yip KW; Liu FF
PLoS One; 2014; 9(5):e98557. PubMed ID: 24853121
[TBL] [Abstract][Full Text] [Related]
138. Inhibitor of differentiation 1 contributes to head and neck squamous cell carcinoma survival via the NF-kappaB/survivin and phosphoinositide 3-kinase/Akt signaling pathways.
Lin J; Guan Z; Wang C; Feng L; Zheng Y; Caicedo E; Bearth E; Peng JR; Gaffney P; Ondrey FG
Clin Cancer Res; 2010 Jan; 16(1):77-87. PubMed ID: 20028744
[TBL] [Abstract][Full Text] [Related]
139. Opposite effects of the triple target (DNA-PK/PI3K/mTOR) inhibitor PI-103 on the radiation sensitivity of glioblastoma cell lines proficient and deficient in DNA-PKcs.
Djuzenova CS; Fischer T; Katzer A; Sisario D; Korsa T; Steussloff G; Sukhorukov VL; Flentje M
BMC Cancer; 2021 Nov; 21(1):1201. PubMed ID: 34763650
[TBL] [Abstract][Full Text] [Related]
140. The Histone Deacetylase Inhibitor Romidepsin Spares Normal Tissues While Acting as an Effective Radiosensitizer in Bladder Tumors in Vivo.
Paillas S; Then CK; Kilgas S; Ruan JL; Thompson J; Elliott A; Smart S; Kiltie AE
Int J Radiat Oncol Biol Phys; 2020 May; 107(1):212-221. PubMed ID: 31987970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
